Drug discovery pipeline
Our pipeline includes novel drug targets with genetic linkage and indication expansion opportunities at all stages of development - all with highly specific patient stratification biomarkers.
Therapeutic area
Indication
Patient stratification biomarkers
Novel targets
Repositioning opportunities
Active molecules
In vitro hit validation
In vivo hit validation
Ageing
Osteoarthritis
Autoimmune
Rheumatoid Arthritis
See more
See less
High-resolution patient stratification results:
- 520 Disease risk loci
- 250 Risk associated genes mapped to disease associated mechanisms
- >30 Druggable targets
- 57 Known active compounds
Autoimmune
Sjögren’s syndrome
See more
See less
High-resolution patient stratification results:
- 717 Disease risk loci
- 299 Risk associated genes mapped to disease associated mechanisms
- >30 Druggable targets
- 263 Known active compounds
Cardiovascular
Atrial fibrillation
Cardiovascular
Cardiovascular disease
Infectious
COVID-19
See more
See less
High-resolution patient stratification results:
- 158 Disease risk loci
- 88 Risk associated genes mapped to disease associated mechanisms
- 23 Druggable targets
- 59 Known active compounds
Metabolic
Diabetes type 2 complications
See more
See less
High-resolution patient stratification results:
- 35 Disease risk loci
- 20 Risk associated genes mapped to disease associated mechanisms
- 8 Druggable targets
- 120 Known active compounds
Neurological
ALS
See more
See less
High-resolution patient stratification results:
- 73 Disease risk loci
- 33 Risk associated genes mapped to disease associated mechanisms
- 16 Druggable targets
- 19 Known active compounds
Neurological
Alzheimer's disease
See more
See less
High-resolution patient stratification results:
- 267 Disease risk loci
- 113 Risk associated genes mapped to disease associated mechanisms
- >30 Druggable targets
- 732 Known active compounds
Neurological
Migraine
Neurological
Parkinson's disease
See more
See less
High-resolution patient stratification results:
- 707 Disease risk loci
- 341 Risk associated genes mapped to disease associated mechanisms
- >30 Druggable targets
- 2611 Known active compounds
Neuropsychiatric
Schizophrenia
See more
See less
High-resolution patient stratification results:
- 125 Disease risk loci
- 85 Risk associated genes mapped to disease associated mechanisms
- >30 Druggable targets
- 155 Known active compounds
Respiratory
Asthma
(non-T2)
(non-T2)
See more
See less
High-resolution patient stratification results:
- 570 Disease risk loci
- >200 Risk associated genes mapped to disease associated mechanisms
- >30 Druggable targets
- 281 Known active compounds
Respiratory
Asthma
(T2-high)
(T2-high)
Respiratory
COPD
See more
See less
High-resolution patient stratification results:
- 359 Disease risk loci
- 163 Risk associated genes mapped to disease associated mechanisms
- >30 Druggable targets
- >300 Known active compounds
Women’s health
Endometriosis
See more
See less
High-resolution patient stratification results:
- 233 Disease risk loci
- 136 Risk associated genes mapped to disease associated mechanisms
- >30 Druggable targets
- 74 Known active compounds
Last updated May 24, 2023
Indication extensions
We have identified hundreds of indication extension opportunities across all stages of development. These licensable assets have high market value and strong efficacy potential for repositioning into new disease areas using patient stratification biomarkers to match them to clinically relevant patient subgroups.
Therapeutic area
Indication
Repositioning opportunities
Preclinical
Phase 1
Phase 2
Phase 3
Marketed
Autoimmune
Rheumatoid Arthritis
12
4
4
1
1
2
Autoimmune
Inflammatory bowel disease
4
1
1
1
1
Cardiovascular
Cardiovascular disease
3
2
1
Autoimmune
Sjögren’s syndrome
6
1
1
1
3
Infectious
COVID-19
31
4
5
8
4
10
Metabolic
Diabetes type 2 complications
6
2
1
2
1
Neurological
ALS
20
3
4
4
1
8
Neurological
Alzheimer's disease
8
1
4
1
1
1
Neurological
Migraine
9
3
1
2
1
2
Neurological
Parkinson's disease
36
6
6
9
9
6
Neuropsychiatric
Schizophrenia
6
2
1
3
Respiratory
Asthma (non-T2)
5
1
1
2
1
Respiratory
Asthma (T2-high)
12
3
2
2
4
1
Respiratory
COPD
11
4
2
1
4
Women’s health
Endometriosis
51
9
10
14
5
13
Last updated March 30, 2023
Upcoming innovation
We are running new disease studies all the time, adding two new chronic disease indications to our DiseaseBank every month. Contact us to talk about your priorities and discuss partnering opportunities in one of our current or upcoming disease studies.
Partner with us-
Alopecia
-
Vitiligo
-
Age-related macular degeneration
-
Biopolar disorder
-
Chronic fatigue syndrome / ME
- Inflammatory bowel disease
- Interstitial pulmonary fibrosis
- Asthma COPD overlap syndrome
- Uterine fibroids
- Prostate cancer
- Glaucoma
Please view our pipelines on a larger screen or device for the best experience.
Improve and derisk your pharmaceutical innovation
Discuss partnering opportunities with our pipeline of novel drug targets and repositioning opportunities all protected and derisked by unique and highly specific patient stratification biomarkers.